$XCHC .11 X-Change Corp. Quickly Advances to Testing

New Post Public Reply Private Reply Replies (1) Message Board
jstops

[b]$XCHC[/b] .11 X-Change Corp. Quickly Advances to Testing Stage with Its 'Phytiva' Brand of Products

DALLAS,[b] [color=blue]Jan. 31, 2013[/color][/b] /PRNewswire via COMTEX/ -- X-Change Corporation (NASDAQ OTC: XCHC), a U.S. publicly-traded company, through its European joint venture with Dupetit Natural Products, GmbH, announces that within one week the Company will move into the testing stage of development of its unique hemp-based Phytiva brand of products, as the Company prepares to bring these products to European and North American markets.

The first testers of these Phytiva Brand products are ready for production and packaging and will include anti-aging skin care and rejuvenation products, including hemp-based lip balms, supplements, moisturizers, and sunscreen. After testing these products, the Company will aggressively market them for over-the-counter (OTC) sales targeting a wide range of cosmetic and ailment-related usages.

"The Company is moving even more quickly than anticipated in creating testers for its initial hemp-based Phytiva Brand products; therefore, we are excited to announce that these cutting-edge products will be brought to market sooner than expected," said Chad S. Johnson, Esq., Chief Operating Officer of X-Change Corporation.

About X-Change Corp.

X-Change Corp. has acquired both the Phytiva Brand of products and all associated rights and Companies and the European JV with Dupetit from Cannabis Science, Inc. The Phytiva products acquired by X-Change Corp. are unique hemp-inclusive products for skin care and rejuvenation. These are the first products of the company to be released publicly. These initial products include lip balms, extracts, supplements, and dermal creams, targeting a wide range of cosmetic and ailment-related usages.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Gnosis Lab's Grand Re-Opening: A New Era for Diagnostics

Updated Category News Views 260

Gnosis Lab Grand Re-Opening Celebration Gnosis, a modern diagnostic laboratory previously known as Mountain View Medical Laboratory, is excited to announce its grand re-opening at its flagship location. This event signifies a crucial transition for the lab as it seeks to blend years of reliable community service with a fresh identity and enhanced capabilities. Commitment...

Continue Reading
New Propane Contract Boosts Titan NRG (TTNN) Growth

Updated Category Stocks Views 404

Titan NRG, Inc. Announces Major Propane Contract Secured Titan NRG, Inc. (OTC: TTNN) has a big contract for the 150,000 gallons of propane supply. Given to one of its subsidiaries, this contract represents a significant turning point for the business. Under this contract, propane will be delivered over the next year to a southern Arizona reservation. Crucially in securing...

Continue Reading
Bitcoin Price Decline: Impact of DOJ and Economic Conditions

Updated Category News Views 259

Bitcoin Price Experiences a Notable Decline Bitcoin has recently faced a serious downturn, falling to around $93,925 as fears surrounding U.S. interest rate changes and potential government sales of Bitcoin emerged. This has created a concerning environment for cryptocurrency investors, highlighting the volatility of digital assets. Market Sentiment and Economic Shifts...

Continue Reading
Cogitate and One Inc Team Up to Revolutionize Payments

Updated Category News Views 169

Cogitate Partners with One Inc to Transform Digital Payments -Customers Enjoy a Seamless Experience by Unifying All Payment Flows into One Comprehensive Platform- Cogitate, a provider of cloud-native core policy, billing, and claims applications for insurers, is excited to announce its partnership with One Inc, the leading digital payments network specifically for the...

Continue Reading
Alnylam Pharmaceuticals Achieves New Stock Milestone of $287.88

Updated Category News Views 74

Alnylam Pharmaceuticals Reaches Record Stock Price Alnylam Pharmaceuticals Inc. has recently made headlines after its stock price reached a remarkable all-time high of $287.88. This surge demonstrates a substantial increase in investor confidence, bolstered by an impressive 1-year change of 71.84% in the company's stock. Known for its groundbreaking work in RNA...

Continue Reading